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Beijing, Hangzhou, Nanjing, Changchun, Shenyang, and Shanghai, ChinaObjectives The intention of the PEPCAD China ISR (A Prospective, Multicenter, Randomized Trial of
Paclitaxel-Coated versus Paclitaxel-Eluting Stent for the Treatment of Drug-Eluting Stent In-Stent
Restenosis) was to demonstrate the efﬁcacy of paclitaxel-coated balloon (PCB) angioplasty in
a non-European patient population with coronary drug-eluting stent in-stent restenosis (DES-ISR).
Background The treatment of DES-ISR is still challenging with no established best strategy. Moreover,
there is no study on the effect of PCB in the treatment of ISR in the Chinese population.
Methods PEPCAD China ISR was a 220-patient randomized (1:1), single-blind prospective multicenter
trial conducted in China. Patients with coronary DES-ISR received either PCB (SeQuent Please, B. Braun
Melsungen AG, Melsungen, Germany) or paclitaxel-eluting stent (Taxus Liberté, Boston Scientiﬁc,
Natick, Massachusetts) treatment. The primary endpoint was in-segment late lumen loss at 9 months.
Results There were no signiﬁcant baseline differences between both treatment groups in terms of
patient, lesion, or procedural characteristics. At 9 months, in-segment late lumen loss in the PCB group
was noninferior to that of the paclitaxel-eluting stent group (0.46  0.51 mm vs. 0.55  0.61 mm;
difference: 0.06 mm with 95% conﬁdence interval: 0.23 to 0.10; p for noninferiority ¼ 0.0005). The
9-month rate of binary restenosis and 12-month composite clinical event rates were not signiﬁcantly
different between groups.
Conclusions In a randomized trial of 220 patients, angioplasty with a PCB was noninferior to
paclitaxel-eluting stent implantation when used to treat DES-ISR. On the basis of these, as well as
previous randomized trial data, PCB angioplasty offers an effective treatment for DES-ISR without the
necessity of implanting additional metal layers for drug release. (A Safety and Efﬁcacy Study of
Paclitaxel-Eluting Balloon to Paclitaxel-Eluting Stent [PEPCAD]; NCT01622075) (J Am Coll Cardiol Intv
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Abbreviations
and Acronyms
BMS = bare-metal stent(s)
CI = conﬁdence interval(s)
DES = drug-eluting stent(s)
ISR = in-stent restenosis
LLL = late lumen loss
MLD = minimal lumen
diameter(s)
PCB = paclitaxel-coated
balloon(s)
PES = paclitaxel-eluting
stent(s)
TLF = target lesion failure
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205Previous studies have shown that paclitaxel-coated balloon
(PCB) angioplasty (Paccocath, Bavaria Medizin Techno-
logy, Oberpfaffenhofen, Germany) is safe and effective in
treating coronary bare-metal stent in-stent restenosis (BMS-
ISR) (1–5), which led to a class IIa, level B recommendation
by the European Society of Cardiology for BMS-ISR (6)
with long-term clinical beneﬁts up to 5 years (7).
There are emerging data regarding the use of PCB
angioplasty for the treatment of coronary drug-eluting stent
(DES) ISR as well. These data currently comprise a small-
scale Japanese study by Habara et al. (8), the PEPCAD-
DES (Treatment of DES In-Stent Restenosis With
SeQuent Please Paclitaxel-Eluting PTCA Catheter) trial
(9), and the ISAR DESIRE 3 (Intracoronary Stenting and
Angiographic Results: Drug-Eluting Stents for In-Stent
Restenosis: 3 Treatment Approaches) trial (10). In these
trials (8–10), PCB, compared with conventional balloon
angioplasty, revealed signiﬁcantly lower late lumen loss
(LLL) and major adverse cardiac events. In addition, in the
ISAR DESIRE 3 trial (10), PCB angioplasty was demon-
strated to be noninferior to paclitaxel-eluting stent (PES)
implantation for DES-ISR.
Despite the obvious beneﬁt of not adding additional metal
layers to an ISR lesion, DES were studied for the use in DES-
ISR relative to their eluted drugs. Cosgrave et al. (11) found
that repeat DES implantation in DES-ISR did not differ
when the eluted drug was changed compared with the use of
the same DES in the original DES-ISR (e.g., PES for PES).
In contrast, Alfonso et al. (12) could not conﬁrm these results
and suggested the implantation of a different type DES for
DES-ISR (e.g., PES after sirolimus-eluting stents). Due to
these conﬂicting results and the attractive stent-free treatment
of theDES-ISRoption, PCB angioplasty was chosen to be the
treatment group compared with PES for obvious methodo-
logical reasons. A highly undervalued aspect of clinical trials is
the increasing regulatory complexity of emerging markets and
potential bias due to ethnically selected patient populations
(13). Therefore, this trial was also designed to adequately
conﬁrm the validity of previous study results in a Chinese
patient population. Besides the conﬁrmation of the clinical and
angiographic results from a large European trial (10), the
PEPCAD China ISR (A Prospective, Multicenter,
Randomized Trial of Paclitaxel-Coated Balloon versus Pacli-
taxel-Eluting Stent for the Treatment of Drug-Eluting Stent
In-Stent Restenosis) was also designed to meet Chi-
nese regulatory requirements for the approval of the used
PCB study device.
Methods
Study design. PEPCAD China ISR is a randomized (1:1),
single-blind, prospective, multicenter trial conducted at 17
Chinese study sites. Patients received either PCB (SeQuent
Please, B. Braun Melsungen AG, Melsungen, Germany)or PES (Taxus Liberté, Boston Scientiﬁc, Natick, Massa-
chusetts) treatment. Major inclusion criteria were as
follows: age 18 to 80 years; DES restenosis patterns
Mehran types I to III (14); reference diameters 2.5 to 4.0
mm; length 30 mm; and percentage of diameter stenosis
70% or 50% with documented myocardial ischemia.
Major exclusion criteria included the following: acute
myocardial infarction within 1 week; bifurcation with
side branch diameter 2.5 mm; evidence of extensive
thrombus in the target vessel; severe chronic heart failure
or New York Heart Association class IV; severe valvular
heart disease; stroke within 6 months prior to the proce-
dure; and/or severe renal failure (glomerular ﬁltration
rate <30 ml/min). The baseline medical therapies
including, for example, nitrates, beta-blockers, and statins
were routinely used according to guidelines. Aspirin 300
mg was given orally within 24 h before the procedure.
Clopidogrel was given at a dose of 300 mg 6 h before the
procedure or 75 mg/day 3 days before the procedure. After
the procedure, dual antiplatelet
therapy (aspirin 100 mg/day
indeﬁnitely and clopidogrel 75
mg/day for at least 12 months)
was recommended.
The primary endpoint was
in-segment LLL at 9 months.
Secondary endpoints included:
rates of acute success (device,
lesion, and procedural success);
9-month percentage of diameter
stenosis; 9-month binary reste-
nosis rate; and in-device LLL
at 9 months. Furthermore, sec-
ondary endpoints were the rates
of target lesion failure (TLF) at
1, 6, 9, and 12 months. TLF was deﬁned as the composite
of cardiac death, target vessel myocardial infarction, or
ischemia-driven target lesion revascularization. In addition,
deﬁnite/probable stent thrombosis rates deﬁned by the
Academic Research Consortium were documented. The
protocol was approved by all ethics committees responsible
for all participating centers (see Online Appendix). An
independent clinical event committee consisting of 3 non-
study-site participants evaluated potential device- or proce-
dure-related adverse and serious adverse events. All patients
gave written informed consent prior to randomization.
Quantitative coronary angiography. Angiographic measure-
ments were conducted ofﬂine with the QAngio XA software
(version 7.2, Medis, Leiden, the Netherlands) at an expe-
rienced core lab (CCRF, Beijing Co. Ltd., Beijing, China).
The core lab was blinded relative to the treatment groups.
Angiographic measurements were done separately at the
target lesion over the entire length of the study device,
within 5 mm proximal and distal of the target lesion, and
12-Month Clinical Follow-up*
n/N=109/109 (100%)
12-Month Clinical Follow-up*
n/N=106/106 (100%)
Paclitaxel-Coated Balloon (PCB, N=109)
♦ 1 implanted PES
Paclitaxel-Eluting Stent (PES, N=106)
♦ 2 implanted other stents
♦ 2 treated with PCB
Clinical Follow-up at 30-day, 6-month, 9-month
n/N=109/109 (100%)
Clinical Follow-up at 30-day, 6-month, 9-month
n/N=106/106 (100%)
9-Month Angiographic Follow-up*
n/N=93/109 (85.3%)
9-Month Angiographic Follow-up*
n/N=82/106 (77.4%)
Analyzed:
ITT - PCB vs. PES=109:106
ATS - PCB vs. PES=110:103
Paclitaxel-Coated Balloon (PCB)
N=110
Paclitaxel-Eluting Stent (PES)
N=110
220 DES In-Stent Restenosis Patients Enrolled from 17 Chinese 
Centers and Randomly Assigned to Either Paclitaxel-Coated 
Balloon (PCB) or Paclitaxel-Eluting Stent (PES) Group in 1:1 Fashion
Excluded:
1 withdrawal of written
informed consent
Excluded:
4 withdrawals of written 
informed consent
Figure 1. Patient Flow Chart
The follow-up window for 9-month angiographic follow-up and 12-month clinical follow-up were  30 days. Analysis was based on both ITT and ATS population.
*Follow-up window:  30 days. ATS ¼ as-treated-set; DES ¼ drug-eluting stent(s); ITT ¼ intention-to-treat; PCB ¼ paclitaxel-coated balloon; PES ¼ paclitaxel-eluting
stent(s).
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206over the entire segment. Restenosis patterns were classiﬁed
according to their focal or diffuse patterns as commonly
applied in patients with DES-ISR (8,9).
Statistical planning and analyses. All statistical analyses were
done at the Division of Biometrics, National Center for
Cardiovascular Diseases of China (Beijing, China).
The primary objective was to demonstrate the non-
inferiority of the in-segment LLL after PCB angioplasty
compared with the corresponding LLL following PES
implantation. The estimated in-segment LLL of PES was
0.45  0.50 mm, the noninferiority margin of LLL was pre-
speciﬁed as 0.22 mm. Under the 1-sided signiﬁcance level
alpha of 0.025 and an estimated 25% loss to angiographic
follow-up, 220 patients will yield 80% power to detectnoninferiority of PCB treatment versus PES implantation.
For angiographic endpoints, a lesion-based analysis was
planned.
Continuous variables were expressed as mean  SD and
compared by the Student t test. Categorical variables were
expressed as frequencies and percentages and were compared
by the chi-square test or Fisher exact test. The analysis of
covariance was used as the primary analysis for LLL. The
pre-speciﬁed covariates in this model were post-procedural
MLD and study site. After eliminating the nonsigniﬁcant
interaction between treatment and study site, the difference
of the LLL between the 2 groups as well as the 95% conﬁ-
dence intervals (CIs) would be estimated by the least-square
estimation. Cumulative incidence of TLF at 12 months
Table 1. Baseline Demographics
PCB
(n ¼ 109)
PES
(n ¼ 106)
p
Value
Age, yrs 61.8  9.3 62.1  9.3 0.83
Male 80.7 (88) 81.1 (86) 0.94
Hypertension 71.6 (78) 65.1 (69) 0.31
Hyperlipidemia 34.9 (38) 33.0 (35) 0.78
Diabetes mellitus 40.4 (44) 33.0 (35) 0.26
Insulin-requiring 12.8 (14) 8.5 (9) 0.30
Current smoker 21.1 (23) 25.5 (27) 0.73
Family history of CAD 11.9 (13) 5.7 (6) 0.11
Previous MI 48.6 (53) 34.9 (37) 0.04
Previous CABG 2.8 (3) 0 (0) 0.25
Stable angina 19.3 (21) 29.2 (31) 0.09
Unstable angina 64.2 (70) 57.5 (61) 0.32
Silent ischemia 14.7 (16) 12.3 (13) 0.60
LVEF, % 61.7  8.50 62.3  8.60 0.66
Values are mean  SD or % (n).
CABG ¼ coronary artery bypass graft; CAD ¼ coronary artery disease; LVEF ¼ left ventricular
ejection function; MI ¼ myocardial infarction; PCB ¼ paclitaxel-coated balloon; PES ¼ pacli-
taxel-eluting stent.
Table 2. Baseline Lesion Characteristics
PCB
(n ¼ 113)
PES
(n ¼ 108)
p
Value
Diagnostic coronary ﬁndings 0.42
Single-vessel disease 78.0 (85/109) 79.2 (84/106)
Two-vessel disease 22.0 (24/109) 18.9 (20/106)
Three-vessel disease 0.0 (0/109) 1.9 (2/106)
Target vessels 0.08
LAD 41.6 (47) 56.5 (61)
LCX 18.6 (21) 12.0 (13)
RCA 39.8 (45) 31.5 (34)
ISR classiﬁcation 0.41
Articulation 8.8 (10) 8.3 (9)
Focal margin 21.2 (24) 14.8 (16)
Focal body 34.5 (39) 31.5 (34)
Multifocal 3.5 (4) 3.7 (4)
Diffuse 18.6 (21) 20.4 (22)
Proliferative 13.3 (15) 17.6 (19)
Occlusive 0.0 (0) 3.7 (4)
Bifurcation lesions 11.5 (13) 13.0 (14) 0.74
Pre-procedure QCA
Reference vessel diameter, mm 2.66  0.38 2.72  0.44 0.3
Lesion length, mm 12.52  6.55 13.08  7.13 0.54
Minimal lumen diameter, mm 0.85  0.38 0.86  0.41 0.86
Diameter stenosis, % 68.26  12.47 68.43  13.25 0.92
Values are % (n/N), % (n), or mean  SD.
ISR ¼ in-stent restenosis; LAD ¼ left anterior descending artery; LCX ¼ left circumﬂex;
QCA ¼ quantitative coronary angiography; RCA ¼ right coronary artery; other abbreviations as
in Table 1.
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207was estimated by the Kaplan-Meier method and compared
with the log-rank test. All signiﬁcant levels were 0.05, and
all analyses were performed with SAS (version 9.13, SAS
Institute, Cary, North Carolina).
Results
Between March 25, 2011 and April 16, 2012, 220 patients
were randomized to either PCB treatment or PES implan-
tation. Five patients withdrew their informed consent
forms, leaving 109 patients for PCB treatment and 106 for
PES implantation (Fig. 1). Baseline cardiovascular risk
factors did not differ signiﬁcantly between the 2 randomized
study groups (Table 1).
In the PCB group, 113 lesions (Table 2) were treated,
whereas in the PES control group, 108 stents were
implanted. There were no signiﬁcant differences of target
vessel distributions and Mehran classiﬁcations. Neither
reference vessel diameters (2.66  0.38 mm, 2.72  0.44
mm, p ¼ 0.33) nor lesion lengths (12.52  6.55 mm, 13.08
 7.13 mm, p ¼ 0.54) were signiﬁcantly different between
groups. Likewise, minimal lumen diameters (MLD) and
percentages of diameter stenosis behaved similarly.
Relative to the procedural and device characteristics
(Table 3), study device balloon pressures were lower when
the PCB was used (PCB: 12.4  3.3 atm vs. PES: 13.5 
2.7 atm, p ¼ 0.008). Moreover, balloon inﬂation times were
signiﬁcantly longer in the PCB group (PCB: 44.5  13.1 s
vs. PES: 14.0  10.8 s, p < 0.0001). The most important
lesion morphological differences were the post-procedural
in-device MLD, which was signiﬁcantly lower in the group
PCB (2.39  0.37 mm vs. 2.56  0.44 mm, p ¼ 0.003)than in the PES group. The percentage of diameter stenosis
was higher after PCB treatment than after PES implanta-
tion (10.5  7.2% vs. 7.1  6.3%, p < 0.001). The acute in-
device lumen gain, however, was lower after PCB treatment
than with PES implantation (1.54  0.43 mm vs. 1.70 
0.47 mm, p ¼ 0.009). Among the 113 lesions in the PCB
group, BMS bailout stenting procedures because of edge
dissections were performed in 5 lesions (4.4%). Device and
lesion crossing success rates did not differ between groups.
In both groups, most ISR treated were the result of limus-
releasing stents (e.g., Cypher, Cordis Corp., Miami Lakes,
Florida; Firebird, Microport Co. Ltd., Shanghai, China;
Excel, JW Medical Systems, Weihai, China), whereas the
remainder were PES-ISR (PCB: 97.3% vs. PES: 98.1%).
Deﬁnite or probable stent thrombosis rates were not
different between the 2 groups during the ﬁrst 12 months
following percutaneous coronary intervention.
Angiographic follow-up results (Table 4) were obtained in
80% of the total study population. MLD before, after, and at
the 9-month follow-up (Fig. 2) were similar. The primary
endpoint in-segment LLL did not differ between PCB and
PES treatment (0.46  0.51 mm vs. 0.55  0.61 mm,
difference: 0.06 mm; 95% CI: –0.23 to 0.10; p for
noninferiority ¼ 0.0005). Except for the proximal edge
Table 4. Angiographic Follow-Up Results at 9 Months
PCB
(n ¼ 93)
PES
(n ¼ 82)
p
Value
Lesion 97 84
Reference vessel diameter, mm
In-device 2.59  0.37 2.62  0.45 0.67
Proximal edge 2.78  0.37 2.83  0.45 0.48
Distal edge 2.47  0.38 2.43  0.52 0.62
In-segment 2.54  0.37 2.56  0.45 0.78
Diameter stenosis, %
In-device 28.76  20.93 27.72  25.58 0.76
Proximal edge 5.56  9.40 13.32  16.26 <0.001
Distal edge 10.84  18.83 13.25  20.50 0.41
In-segment 28.97  21.30 30.83  25.27 0.59
Minimal lumen diameter, mm
In-device 1.85  0.60 1.89  0.75 0.66
Proximal edge 2.63  0.43 2.45  0.61 0.03
Distal edge 2.20  0.59 2.14  0.66 0.50
In-segment 1.80  0.58 1.76  0.71 0.69
Late lumen loss, mm
In-device 0.54  0.46 0.62  0.68 0.36
Proximal edge 0.10  0.30 0.27  0.41 0.002
Distal edge 0.20  0.42 0.25  0.44 0.44
In-segment 0.46  0.51 0.55  0.61 0.32
Binary restenosis
In-device 17.5 (17) 21.4 (18) 0.51
Proximal edge 1.0 (1) 2.4 (2) 0.60
Distal edge 4.1 (4) 6.0 (5) 0.74
In-segment 18.6 (18) 23.8 (20) 0.39
Mehran classiﬁcation 0.36
Focal margin 11.1 (2) 5.0 (1)
Focal body 61.1 (11) 40.0 (8)
Multifocal 0.0 (0) 5.0 (1)
Diffuse 11.1 (2) 35.0 (7)
Occlusive 16.7 (3) 15.0 (3)
Binary ISR classiﬁcation 0.16
Focal 72.2 (13) 50.0 (10)
Diffuse 27.8 (5) 50.0 (10)
Values are n, mean  SD, or % (n).
Abbreviations as in Tables 1 and 2.
Table 3. Procedural and Device Characteristics
PCB
(n ¼ 113)
PES
(n ¼ 108)
p
Value
Balloon pre-dilation 99.1 (112) 99.1 (107) 1.00
Length, mm 13.15  3.42 12.96  3.27 0.67
Diameter, mm 2.85  1.32 2.66  0.49 0.15
Pressure, atm 14.50  4.42 13.85  4.48 0.28
Inﬂation time, s 11.84  7.71 13.33  19.05 0.45
Study device 120 108
Length, mm 19.73  5.88 20.12  7.07 0.65
Diameter, mm 3.06  0.39 2.98  0.39 0.13
Pressure, atm 12.4  3.3 13.5  2.7 0.008
Inﬂation time, s 44.5  13.1 14.0  10.8 <0.0001
Post-procedure QCA
Reference vessel diameter, mm 2.59  0.40 2.67  0.44 0.17
Minimal lumen diameter, mm
In-device 2.39  0.37 2.56  0.44 0.003
Proximal edge 2.73  0.46 2.73  0.51 0.98
Distal edge 2.38  0.45 2.38  0.49 0.90
In-segment 2.25  0.38 2.32  0.47 0.21
Diameter stenosis, %
In-device 10.51  7.22 7.05  6.28 <0.001
Proximal edge 5.39  6.82 8.56  7.95 0.002
Distal edge 7.25  7.73 10.17  8.43 0.008
In-segment 12.86  8.34 13.00  8.75 0.91
Acute gain, mm
In-device 1.54  0.43 1.70  0.47 0.009
In-segment 1.40  0.44 1.47  0.50 0.29
Device success 99.2 (119) 100.0 (108) 1.00
Lesion success 100.0 (113) 100.0 (108) d
Values are n, mean  SD, or % (n). Dash indicates data were not available.
Abbreviations as in Tables 1 and 2.
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208MLD and the proximal edge LLL, there were no differences
in any quantitative coronary angiography parameters (Online
Table 1). MLD at the proximal ISR edge in the PCB group
was larger (2.63  0.43 mm vs. 2.45  0.61 mm, p ¼ 0.03)
and the proximal edge LLL was lower (0.10  0.30 mm vs.
0.27  0.41 mm, p ¼ 0.002) as compared with the corre-
sponding results after PES implantation.
Patterns of restenosis according to Mehran classiﬁcation
did not differ between study groups. Nevertheless, the focal
versus diffuse pattern analysis revealed that there were
numerically more focal ISR patterns associated with PCB
angioplasty than with PES implantation (72.2% vs. 50.0%);
however, these were not statistically signiﬁcant (p ¼ 0.16).
Clinical results at 12 months. Clinical results at 1 and 12
months (Table 5) did not differ between the 2 groups in the
intention-to-treat or as-treated-set analyses. The main
driver for TLF at 12 months was target lesion revasculari-
zation. The 12-month TLF rates in the as-treated-set
analysis were 15.5% (17 of 110) in PCB patients and 17.5%
(18 of 103) in the PES group (p ¼ 0.69). In the absence of
cardiac death, the myocardial infarction rates were 2.7%(3 of 110) and 6.8% (7 of 103) in the PCB and PES groups,
respectively (p ¼ 0.20).
Referring to the Kaplan-Meier analyses (Fig. 3), there
were no differences in the cumulative composite incidence
rates consisting of cardiac death, target vessel myocardial
infarction, and ischemia-driven target lesion revasculariza-
tion in the intention-to-treat analysis (p ¼ 0.87) and in the
as-treated-set analysis (p ¼ 0.51).Discussion
The results of this moderate-sized randomized trial of PCB
angioplasty versus PES for DES-IRS demonstrated that
Figure 2. Cumulative Distributions of In-Segment MLD in the ITT Analysis:
PCB Versus PES
ITT ¼ intention-to-treat; MLD ¼ minimal lumen diameter(s); post ¼ post-
procedure; pre ¼ pre-procedure; other abbreviations as in Figure 1.
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209PCB angioplasty was noninferior in terms of in-segment
LLL to PES implantation in patients with DES-ISR.
Additionally, the rates of adverse clinical events were similar
between both treatment groups with 12-month clinical
follow-up. Overall, these results, obtained entirely within
a Chinese patient population, are in agreement with previous
studies that have compared PCB angioplasty withTable 5. Clinical Results at 1 Month and 12 Months
ITT
1 Month 12
PCB
(n ¼ 109)
PES
(n ¼ 106) p Value
PCB
(n ¼ 109)
Death 0.0 (0) 0.0 (0) d 0.0 (0)
Cardiac death 0.0 (0) 0.0 (0) d 0.0 (0)
Noncardiac death 0.0 (0) 0.0 (0) d 0.0 (0)
Myocardial infarction 2.8 (3) 5.7 (6) 0.33 3.7 (4)
Q-wave MI 0.0 (0) 0.0 (0) d 0.0 (0)
Non–Q-wave MI 2.8 (3) 5.7 (6) 0.33 3.7 (4)
Target vessel MI 2.8 (3) 5.7 (6) 0.33 2.8 (3)
Ischemia-driven TLR 0.9 (1) 0.9 (1) 1.00 14.7 (16)
TLR 1.8 (2) 0.9 (1) 1.00 15.6 (17)
TVR 1.8 (2) 0.9 (1) 1.00 16.5 (18)
Any revascularization 1.8 (2) 0.9 (1) 1.00 22.0 (24)
Device-oriented composite endpoint, TLF 3.7 (4) 6.6 (7) 0.33 16.5 (18)
Patient-oriented composite endpoint 4.6 (5) 6.6 (7) 0.52 23.9 (26)
Deﬁnite or probable stent thrombosis 0.0 (0) 0.0 (0) d 0.9 (1)
Values are % (n). Dashes indicate that data were not available. Patient-oriented composite endpoint in
included: cardiac death; target-vessel MI; or ischemia-driven TLR.
ATS ¼ as-treated-set analysis; ITT ¼ intention-to-treat analysis; MI ¼ myocardial infarction; TLF ¼ targ
abbreviations as in Table 1.conventional balloon angioplasty (7–10) and to repeat DES
implantation (10).
Although ISR occurs with a lower frequency among
patients treated with DES than with BMS, when ISR
occurs, it can lead not only to a recurrence of stable angina
symptoms but in some cases has also been associated with
unstable angina and/or myocardial infarction (15,16). The
majority of patients with ISR additionally have to undergo
repeat revascularization procedures by either percutaneous
coronary intervention or coronary artery bypass graft, and
even after repeat percutaneous coronary intervention, the
rate of recurrence of ISR is higher than among patients with
de novo DES implantation (11). As a result, there remains
active interest in therapies that are both effective and safe at
treating DES-ISR.
Whereas repeat DES implantation is a viable strategy for
the treatment of DES-ISR, it is intuitively appealing to
avoid placement of another metal layer within an existing
stent with ISR. The original PCB technology that was
used in this trial (SeQuent Please, Paccocath) has a drug
concentration of 3 mg/mm2 paclitaxel embedded in an
iopromide spacer matrix (17).
In this study, we demonstrated noninferiority of PCB
angioplasty to PES for the treatment of DES-ISR.
Although noninferiority of late loss was demonstrated, we
did measure 0.46 mm for in-segment late loss, which is
somewhat higher than the analogous LLL of 0.32 mm by
Rittger et al. (9) and 0.37 mm by Byrne et al. (10).ATS
Months 1 Month 12 Months
PES
(n ¼ 106) p Value
PCB
(n ¼ 110)
PES
(n ¼ 103)
p
Value
PCB
(n ¼ 110)
PES
(n ¼ 103)
p
Value
1.9 (2) 0.24 0.0 (0) 0.0 (0) d 0.0 (0) 1.9 (2) 0.23
0.0 (0) d 0.0 (0) 0.0 (0) d 0.0 (0) 0.0 (0) d
1.9 (2) 0.24 0.0 (0) 0.0 (0) d 0.0 (0) 1.9 (2) 0.23
6.6 (7) 0.33 2.7 (3) 5.8 (6) 0.32 3.6 (4) 6.8 (7) 0.30
0.9 (1) 0.49 0.0 (0) 0.0 (0) d 0.0 (0) 1.0 (1) 0.48
5.7 (6) 0.53 2.7 (3) 5.8 (6) 0.32 3.6 (4) 5.8 (6) 0.53
6.6 (7) 0.21 2.7(3) 5.8 (6) 0.32 2.7 (3) 6.8 (7) 0.20
10.4 (11) 0.34 0.9 (1) 1.0 (1) 1.00 13.6 (15) 11.7 (12) 0.66
12.3 (13) 0.48 1.8 (2) 1.0 (1) 1.00 14.5 (16) 13.6 (14) 0.84
16.0 (17) 0.92 1.8 (2) 1.0 (1) 1.00 15.5 (17) 17.5 (18) 0.69
17.9 (19) 0.45 1.8 (2) 1.0 (1) 1.00 20.9 (23) 19.4 (20) 0.79
16.0 (17) 0.92 3.6 (4) 6.8 (7) 0.30 15.5 (17) 17.5 (18) 0.69
23.6 (25) 0.96 4.5 (5) 6.8 (7) 0.48 22.7 (25) 25.2 (26) 0.67
0.9 (1) 1.00 0.0 (0) 0.0 (0) d 0.9 (1) 1.0 (1) 1.00
cluded: all-cause death; all MI; or any revascularization. Device-oriented composite endpoint (TLF)
et lesion failure; TLR ¼ target lesion revascularization; TVR ¼ target vessel revascularization; other
AB
Figure 3. Cumulative Incidence Rates for PCB Versus PES Treatment
(A) Intention-to-treat analysis (n ¼ 215); (B) as-treated analysis (n ¼ 213).
Device-oriented composite events (target lesion failure: cardiac death, target
vessel myocardial infarction, ischemia-driven target lesion revascularization).
Abbreviations as in Figure 1.
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210Nonetheless, PCB angioplasty was very comparable with
PES implantation and, compared with the results obtained
from BMS-ISR populations, the amount of in-segment
LLL can be expected to be twice as high in patients with
DES-ISR. Unfortunately, the assessment of previous
multilayer stenting could not be routinely determined in our
study population during the index procedure.
Despite the lower acute in-device luminal gain (Table 3)
in the PCB group (1.54  0.43 mm vs. 1.70  0.47 mm,
p ¼ 0.009), the in-device MLD at 9-month follow-up
are not signiﬁcantly different (1.85  0.60 mm vs. 1.89 
0.75 mm, p ¼ 0.66), which means that intimal hyperplasia
can be expected to be more pronounced with PES implan-
tation. The other potential ramiﬁcation of this ﬁnding is that
acute angiographic results may appear to be discouraging but
may lead to sustained angiographic beneﬁts at a 9-month
follow-up. This ﬁnding is also supported by the recent
publication by Agostoni et al. (18) that described morpho-
logical and functional outcomes after drug-coated balloonangioplasty for ISR. Interestingly, our MLD curve at follow-
up for the PES patients shows an increased slope for the
bottom 30% of MLD that appears similar to the ﬁndings by
Unverdorben et al. (3), who used the Taxus stent as
a comparator in their PEPCAD II (Paclitaxel-Eluting
PTCA-Balloon Catheter in Coronary Artery Disease II)
trial. It seems that a signiﬁcant subgroup of patients (20% to
30%) do not seem to beneﬁt from stent-mediated paclitaxel
release to treat ISR.
Noticeably, the proximal edge MLD in the PCB group is
larger than that in the PES group, whereas the reference
vessel diameters are similar at 9-month follow-up. This may
be because of the fact that in the PES control group, the
balloon is slightly longer than the actual stent (balloon
overhang), extending over the proximal and distal stent
edges. This, however, may lead to vessel damage proximal
and distal to the stent edge where the drug is not being
released (no stent struts for drug release in balloon-dilated
vessel segments). This, in turn, may lead to further LLL. In
contrast, when using the PCB, all vessel injury in the
balloon-dilated lesion and neighboring segments caused by
either the pre-dilation or the low-pressure PCB dilation is
covered with the drug. This suggests that drug-coated
balloon angioplasty may have less of an edge effect than has
commonly been observed with DES.
Our ﬁndings conﬁrm the results by Byrne et al. (10),
who demonstrated clinically similar results with PCB
angioplasty versus PES implantation. Nevertheless, the
clinical beneﬁt of a stent-free drug release when using PCB
and thereby avoiding additional metal layers seems highly
attractive for a variety of reasons (vaso-motility, less
mechanical irritation, potential to reduce dual antiplatelet
therapy).
Study limitations. The balance of smaller noninferiority
margin versus increasing sample size is always an issue. We
sensed, however, that a clinically acceptable margin was pre-
deﬁned despite the fact that the noninferiority margin was
one-half of the expected effect size. Although this study was
powered for an angiographic endpoint, the number of
patients was not sufﬁcient to detect differences in clinical
endpoints. Despite the fact that patients with DES-ISR
were recruited, the exact type of failed DES could not be
determined in all patients. Moreover, additional imaging
techniques such as optical coherence tomography to obtain
more detailed lesion morphologic data were not feasible for
all patients in this trial.Conclusions
This multicenter, randomized trial demonstrates the safety
and efﬁcacy of PCB angioplasty and noninferiority versus
PES treatment in a non-European study population in need
of ISR treatment after limus-eluting stent failure.
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